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X-linked lymphoproliferative syndrome (XLP) is a rare primary 
immunodeficiency characterized by increased vulnerability to Epstein-Barr virus 
infection. XLP type 1 is caused by mutations in SH2D1A, whereas X-linked inhibitor of 
apoptosis (XIAP) encoded by XIAP/BIRC4 is mutated in XLP type 2. In XIAP deficiency, 
hemophagocytic lymphohistiocytosis (HLH) occurs more frequently and recurrence is 
common. However, the underlying mechanisms remain mostly unknown. We describe 
the characteristics of the cytokine profiles of serum samples from 10 XIAP-deficient 
patients. The concentration of interleukin (IL)-18 was strikingly elevated in the patients 
presented with HLH, and remained high after the recovery from HLH although levels of 
other pro-inflammatory cytokines approached the normal range. Longitudinal 
examination of two patients demonstrated marked exacerbation of IL-18 levels during 
every occasion of HLH. These findings may suggest the association between HLH 
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X-linked lymphoproliferative syndrome (XLP) is a rare primary 
immunodeficiency that is characterized by an extreme susceptibility to Epstein-Barr virus 
infection resulting in fatal infectious mononucleosis or hemophagocytic 
lymphohistiocytosis (HLH), hypogammaglobulinemia, and malignant lymphoma [1-3]. 
Most cases are caused by mutations in the SH2D1A gene, which encodes the signaling 
lymphocyte activation molecule (SLAM)-associated protein (SAP), a cytoplasmic 
adaptor molecule involved in intracellular signaling downstream of the SLAM family of 
surface receptors (XLP type 1). SAP is expressed in T, natural killer (NK), and invariant 
NKT cells [1-3]. A deficiency of X-linked inhibitor of apoptosis (XIAP) caused by 
XIAP/BIRC4 gene mutations has been also identified to cause XLP (XLP type 2) [4]. 
XIAP, a member of the inhibitor of apoptosis family of proteins, plays an antiapoptotic 
role as a potent inhibitor of caspases 3, 7, and 9, and also possesses E3 ubiquitin ligase 
function [1-3].  In contrast to SAP, XIAP is expressed ubiquitously. Patients with XIAP 
deficiency have been reported to develop HLH more frequently compared with SAP 
deficiency [5]. However, it remains unknown why a deficiency of XIAP leads to HLH 
and its recurrence in patients with XIAP deficiency.  
 HLH is a heterogeneous group of diseases that are characterized by uncontrolled 
proliferation of activated macrophages and T cells with overproduction of pro-
inflammatory cytokines [6, 7]. Patients with HLH may present with fever, cytopenia, 
hepatosplenomegaly, liver dysfunction, coagulation abnormalities, and hemophagocytosis. 
[6, 7] HLH is comprised of primary and secondary forms. Primary HLH includes familial 
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HLH (FHL), which is caused by genetic defects related to granule-dependent cytotoxicity, 
and immunodeficiencies, such as XLP. FHL type 2 (FHL2) due to perforin deficiency is 
the most common form of primary HLH [6, 7]. Perforin is a crucial effector molecule for 
cytotoxicity that is present in the granules of cytotoxic T cells and NK cells. Secondary 
HLH is associated with a variety of infections, autoimmune diseases and malignancies. 
Epstein-Barr virus (EBV)-associated HLH (EBV-HLH) is the most frequent subtype of 
secondary HLH in Japan [8]. Studies of cytokines from HLH patients have demonstrated 
elevated concentration of many pro-inflammatory cytokines, such as interferon (IFN)-γ, 
tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-18 [9-11]. 
IL-18 is a potent pro-inflammatory cytokine that was originally identified as an 
IFN-γ-inducing factor [12, 13]. It has been reported that IL-18 induces either Th1 or Th2 
polarization depending on the immunologic context, and promotes a variety of innate 
immune processes associated with infection, inflammation, and autoimmunity [12, 13]. In 
this report, we describe the characteristic cytokine profiles of XIAP deficiency, especially 







We studied 10 patients with XIAP deficiency from 9 families (Table 1). Case 
reports of Pt2.1, Pt2.2, Pt4, Pt5, Pt8, and Pt9 have been described elsewhere [5, 14, 15]. 
Patients Pt2.1, Pt2.2, Pt4, and Pt5 were reported in a previous report as P6.1, P6.2, P1, 
and P3.1, respectively [14]. Patient Pt7 was a younger brother of P2.1 and P2.2 [14]. 
Patients Pt8 and Pt9 were reported in a previous report as Patient 3 and Patient 9, 
respectively [5]. All patients showed typical features of HLH, such as persistent fever, 
cytopenia, liver dysfunction, and hyperferritinemia during the acute phase of HLH. The 
age of onset was variable, ranging from early infancy to 8 years. Most patients were 
treated with corticosteroids with or without cyclosporine A, and showed recurrent HLH. 
Patient Pt3 underwent cord blood transplantation and is alive with no evidence of disease. 
Patients Pt8 and Pt9 underwent allogeneic bone marrow transplantation but died of 
complications [16]. Blood samples were collected during the acute phase of HLH and/or 
during a clinically stable phase. We also investigated 4 cases of SAP deficiency, 6 cases 
of FHL2, and 11 cases of EBV-HLH as disease controls [17]. No detectable mutations 
within the SH2D1A or XIAP/BIRC4 genes were observed in the 5 male patients with 
EBV-HLH [18]. Approval for the study was obtained from the Human Research 
Committee of Kanazawa University Graduate School of Medical Science, and informed 
consent was provided according to the Declaration of Helsinki. 
 
2.2. Analysis of XIAP mutations and protein expression 
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DNA was extracted from blood samples using standard methods. The 
XIAP/BIRC4 gene was amplified from genomic DNA using specific primers [5, 14]. 
Sequencing was performed on purified polymerase chain reaction products using the ABI 
Prism BigDye Terminator Cycle sequencing kit on an ABI 310 or 3130 automated 
sequencer (Applied Biosystems, Foster, CA). Flow cytometric and Western blot analysis 
of intracellular XIAP were performed, as described previously [5, 14]. 
 
2.3. Cytokine determination 
Serum concentrations of cytokines were determined using the following enzyme-
linked immunosorbent assay kits: neopterin (IBL, Hamburg, Germany); IFN-γ, IL-6, and 
TNF-α (R&D systems, Minneapolis, MN); and IL-18 (MBL, Nagoya, Japan) [17, 19]. 
Analysis of differences among groups was performed using the Student’s t-test for 
unpaired samples. Differences with p-values less than 0.05 were considered significant.  
 
2.4. Cell cultures 
Peripheral blood mononuclear cells (PBMCs) were isolated from patients and 
controls by Ficoll-Hypaque gradient centrifugation. To stimulate monocytes, PBMCs 
were incubated with 100 ng/mL lipopolysaccharide (LPS; Sigma-Aldrich, St. Louis, MO) 
with or without 5 mM adenosine triphosphate (ATP; Sigma-Aldrich) in RPMI 1640 
medium containing 10% fetal calf serum and antibiotics [20]. After 24 hours, culture 





3.1. XIAP/BIRK4 mutations and protein expression 
As shown in Table 1, most patients had nonsense or frameshift mutations in the 
XIAP/BIRC4 gene. Patients Pt1 and Pt3 were found to carry novel nonsense mutations, 
c.847C>T (Q283X) and c.664C>T (R222X), respectively. Intracellular XIAP was not 
detected in PBMCs from patient Pt1, whereas residual expression was demonstrated in 
patient Pt3. Patient Pt6 had a novel splice site mutation, c.1056+1G>A, resulting in no 
detectable expression of XIAP.  
 
3.2. Cytokine profiles 
The concentration of IL-18 was markedly elevated in XIAP-deficient patients 
who presented with HLH (mean, 86500 pg/mL; Figure 1A). Children who were affected 
with SAP deficiency, FHL2 or EBV-HLH exhibited much less elevation of IL-18 with 
mean concentrations of 6600 pg/mL (range, 6200 - 7000 pg/mL), 3680 pg/mL (range, 
1300 - 10500 pg/mL) and 4256 pg/mL (range, 3050 - 6950 pg/mL), respectively (Figure 
1A) [17]. Other pro-inflammatory cytokines such as IL-6, neopterin, IFN-γ, and TNF-α 
were elevated in patients with XIAP deficiency, however, levels of these cytokines were 
comparable to those of patients with SAP deficiency, FHL2, or EBV-HLH (Figure 1A). 
The levels of soluble IL-2 receptor were also elevated in patients with XIAP deficiency 
(mean, 2910 IU/mL). 
As expected, after the recovery from HLH, the concentration of each pro-
inflammatory cytokine declined in patients with SAP deficiency, FHL2 and EBV-HLH. 
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However, as XIAP-deficient patients recovered from HLH, serum IL-6, neopterin, IFN-γ, 
and TNF-α levels approached the normal range but the levels of IL-18 remained high in 
these patients (mean, 4090 pg/mL; Figure 1A). Longitudinal examination of the cytokine 
profiles in patients Pt1 and Pt2.1 clearly demonstrated sustained elevation of IL-18 and 
its marked exacerbation on every occasion of recurrent HLH (Figure 1B).  
 
3.3. Secretion of IL-18 from PBMCs after in vitro stimulation 
To assess whether hypersecretion of IL-18 was observed from monocytes after 
inflammasome stimulation, PBMCs from normal individuals and 3 patients with XIAP 
deficiency (Pt1, Pt2.1, and Pt2.2) were cultured for 24 hours with LPS and ATP. 
Consistent with previous observations [20], IL-18 was efficiently secreted in normal 
PBMCs after stimulation with LPS plus ATP (Figure 2), although TNF-α and IL-1β were 
produced in response to stimulation with only LPS (data not shown). There was little 
production of IL-18 in PBMCs from patients with XIAP deficiency after stimulation with 
LPS as well as no stimulation, suggesting no spontaneous production of IL-18. More 
importantly, levels of IL-18 secretion after stimulation with LPS plus ATP in PBMCs 





XIAP deficiency is characterized by a high incidence of HLH [1-3]. Most patients 
suffer from recurrent HLH, although the reason for the increase in HLH susceptibility 
remains unknown. To further characterize the disease, we investigated the cytokine 
profiles during the acute phase of HLH and during a clinically stable phase from 10 
patients with XIAP deficiency and compared them to patients with SAP deficiency, 
FHL2 (perforin deficiency), and EBV-HLH. 
Hypersecretion of pro-inflammatory cytokines from activated T cells and 
macrophages has been considered to account for the severe systemic symptoms of HLH 
[6, 7]. Indeed, during the acute phase of HLH, patients exhibited hypercytokinemia, i.e., 
IL-6, IL-18, neopterin, IFN-γ, and TNF-α, regardless of underlying genetic disease. 
However, compared with our previous studies of cytokines in other forms of HLH [17], 
the concentration of IL-18 was strikingly elevated during HLH and remained high after 
the recovery from HLH in XIAP-deficient patients. Patients Pt2.2 and Pt5, both of whom 
had disease for longer than 10 years, also showed high IL-18 levels during the clinically 
stable phase, indicating that this characteristic appears to be consistent and stable in the 
patients. No correlation was observed between the concentration of IL-18 and the levels 
of residual XIAP protein expression. In addition, the level of IL-18 declined to within the 
normal range (142 pg/mL) in patient Pt3 only after successful stem cell transplantation. 
Taken together, these findings may indicate the association between HLH susceptibility 
in XIAP deficiency and high serum levels of IL-18 and the possible role of serum IL-18 
as a marker of disease activity. 
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Similar cytokine profiles have recently been described in patients with systemic 
juvenile idiopathic arthritis (sJIA) and with adult-onset Still’s disease (AOSD), which 
also showed persistent high levels of serum IL-18 [19, 21-26]. sJIA is a systemic 
inflammatory disease classified within the spectrum of JIA and is characterized by fever, 
rash and arthritis [12]. AOSD is likely to be the adult counterpart of sJIA [12]. In both 
diseases, macrophage activation syndrome, a form of HLH associated with rheumatic 
diseases, occurs frequently [12]. The concentration of IL-18 was further elevated in 
patients with sJIA/AOSD who presented with macrophage activation syndrome [19]. 
These profiles are quite similar to those of XIAP deficiency. Although the etiology of 
sJIA/AOSD remains unknown, these disorders might share a common final pathway of 
abnormal IL-18 secretion. On the other hand, studies of NK cells from patients with sJIA 
have demonstrated that a defect in IL-18 receptor β phosphorylation was involved in 
impaired NK cell function in sJIA [27]. Further studies are necessary to assess whether 
similar defects could exist and contribute to the disease pathogenesis in patients with 
XIAP deficiency. Moreover, it is tempting to speculate that XIAP-deficient patients 
might be misdiagnosed with sJIA/AOSD. In fact, our patient Pt1 was initially given the 
diagnosis of sJIA despite the absence of arthritis (case 4 in reference no. 7). Although 
arthritis may not be prominent, particularly early in the course of sJIA [28], patient Pt1 
has shown no clinical or laboratory evidence of arthritis to date.  
 It is well known that IL-18 is produced mainly by monocytes/macrophages in 
response to a variety of stimuli, and that IL-18 is synthesized as a precursor molecule, 
which is cleaved by the caspase-1 within the inflammasome [12, 13]. However, the 
mechanism underlying the sustained elevation of IL-18 in XIAP deficiency is unclear at 
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present. The cellular source of the IL-18 also remains to be elucidated. Our preliminary 
experiments failed to demonstrate that PBMCs from XIAP-deficient patients secreted 
larger amounts of IL-18 upon stimulation with LPS and ATP, compared with normal 
controls. However, recent evidence suggests that XIAP mediates signaling of nucleotide-
binding and oligomerization domain 2 (NOD2) in inflammation and innate immunity [29-
31]. Because NOD2 can activate caspase-1, it is possible that XIAP is involved in 
inflammasome-mediated IL-18 production. 
It is unknown why a deficiency of XIAP leads to the development of HLH [1-3]. 
Deficiency of XIAP has been observed to result in increased sensitivity of T cells to 
undergo reactivation-induced cell death [4, 5]. Therefore XIAP may function to prevent 
HLH by inhibiting the apoptosis of cells that mediate the clearance of pathogens. 
Decreased numbers of NKT cells may also contribute to the development of HLH similar 
to SAP deficiency (XLP type 1), although there is some controversy over the numbers of 
such populations [32]. In addition, the loss of XIAP may influence immune cell 
activation resulting in alterations in pro-inflammatory cytokine production and cell 
survival in murine studies [33-35]. Because hypersecretion of IL-18 has been reported to 
play important roles in the pathogenesis of HLH [36], sustained elevation of IL-18 and its 
marked exacerbation on HLH in patients with XIAP deficiency would be an additional 
possibility to explain HLH susceptibility in this disease. 
In summary, our studies demonstrate markedly elevated serum levels of IL-18 
that are associated with HLH in XIAP deficiency. Characterization of the mechanism 
underlying the hypersecretion of IL-18 could provide important insights into the 
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Table 1. Patient characteristics. 
 
 Pt1 Pt2.1 b Pt2.2 b Pt3 Pt4 Pt5 Pt6 Pt7 Pt8 Pt9 
 
Nucleotide mutation c.847C>T c.1021_ c.1021_ c.664C>T c.712C>T c.650delG c.1056+1G>A c.1141C>T c.1445C>G c.310C>T 
  1022delAA 1022delAA 
Effect Q283X N341fs N341fs R222X R238X W217fs splice defect R381X P482R Q104X 
Protein expression a negative residual residual residual residual negative negative negative residual negative 
Age at onset 1 mo 17 mo 15 mo 5 mo 20 mo 2 mo 3 yr 8 mo infancy 8 yr 
Current age 5 yr 3 yr 15 yr 2 yr 7 yr 12 yr 9 yr 10 mo deceased deceased 
Family history No Yes Yes No No Yes No Yes No Yes 
HLH + + + + + + + + + + 
Recurrent HLH + + + + + + + - NA + 
Fever + + + + + + + + + + 
Splenomegaly - + + + + - - + + + 
Cytopenia + + + - + + - + + + 
EBV - + + - + + - - - - 
Hypogammaglobulinemia - - - - - - - - - + 
Colitis - - - - + - - - NA NA 
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Lymphoma - - - - - - - - - - 
Treatment PSL, CsA IVIG, Dex PSL Dex, CsA PSL, CsA PSL, CsA PSL Dex, CsA HLH 2004, Dex 
    PSL Dex    including rituximab 
     tocillizumab   IT treatment 
Allogeneic HSCT - - - + - - - - + + 
 
a Intracellular expression of XIAP in lymphocytes was analyzed by flow cytometry or Western blot. b sibling cases.  
HLH, hemophagocytic lymphohistiocytosis; mo, month; yr, year; NA, not applicable; EBV, Epstein-Barr virus; PSL, prednisolone; 
CsA, cyclosporin A; Dex, dexamethasone, IVIG, intravenous immunoglobulin; HSCT, hematopoietic stem cell transplantation. 
Figure Legends 
 
Figure 1.   Cytokine profiles. 
(A) Serum concentrations of interleukin (IL)-18, IL-6 and neopterin were measured in 
patients with X-linked inhibitor of apoptosis (XIAP) deficiency, with signaling 
lymphocyte activation molecule (SLAM)-associated protein (SAP) deficiency, with 
familial hemophagocytic lymphohistiocytosis type 2 (FHL2) due to perforin deficiency, 
and with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). 
Shaded areas represent the ranges of the normal values. (B) Longitudinal examination of 
IL-18 levels. Arrows indicate episodes of HLH. HLH, hemophagocytic 
lymphohistiocytosis; n.s., not significant. * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Figure 2.   IL-18 secretion after in vitro stimulation. 
Peripheral blood mononuclear cells were cultured with lipopolysaccharide (LPS) and 
adenosine triphosphate (ATP) for 24 hours. The levels of IL-18 in culture supernatants 
were measured by enzyme-linked immunosorbent assay. 
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